10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design – Part 2
What if the breakthrough in AI-driven protein therapeutics hinges less on machine learning algorithms and more on a bold rethink of how companies share their most valuable resource—data?
10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design – Part 1
There’s a reason so many “picture-perfect” protein designs never make it past the computer screen: the leap from simulation to real-world function is wider than it looks.
Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge – Part 2
Is a future without heart attacks and strokes within reach—not just delayed, but truly reversed?
Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge – Part 1
What if the boldest therapeutic breakthroughs begin with questioning the very boxes we use to define drugs?
Batch-to-Batch Variability Is a Design Failure, Not the Norm – Part 2
Biotech startups face a labyrinth of decisions when it comes to manufacturing strategy.
Batch-to-Batch Variability Is a Design Failure, Not the Norm – Part 1
What if batch-to-batch variability was no longer just “part of the job” in tissue engineering and in vitro biology?
Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection – Part 2
Cell line development in biotech is a race against time and complexity, with innovators constantly seeking solutions that provide robust and scalable data for manufacturability and regulatory demands.
Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection – Part 1
Cloning workflows have long relied on brute force: screen more cells, automate harder, and hope that small-scale performance predicts manufacturability.
When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2
Biopharma faces mounting pressure to develop safer, more efficient platforms for delivering nucleic acid therapies, especially as regulatory agencies scrutinize novel formulations and excipients.
When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 1
Imagine a delivery system that can slip straight into a cell’s membrane, bypassing the barriers that stop most genetic medicines in their tracks. While AAVs and lipid nanoparticles have charted the way for gene therapies, a new contender is emerging: proteolipid vehicles powered by viral fusion proteins.